HSBC Holdings’s Trevi Therapeutics TRVI Stock Holding History

HSBC Holdings’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$199K	Sell	10,516 -6,518	-38%	-$94.8K	﹤0.01%	2702
2026 Q1	$205K	Buy	+17,034	New	+$191K	﹤0.01%	2601
2025 Q4	–	Sell	-41,634	Closed	-$372K	–	3163
2025 Q3	$372K	Sell	41,634 -20,805	-33%	-$156K	﹤0.01%	2242
2025 Q2	$342K	Buy	62,439 +34,691	+125%	+$216K	﹤0.01%	2365
2025 Q1	$173K	Sell	27,748 -17,005	-38%	-$81.1K	﹤0.01%	2658
2024 Q4	$184K	Buy	44,753 +843	+2%	+$2.7K	﹤0.01%	2743
2024 Q3	$144K	Buy	43,910 +24,298	+124%	+$72.2K	﹤0.01%	2722
2024 Q2	$60.8K	Buy	+19,612	New	+$54.5K	﹤0.01%	2801

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

HSBC Holdings's TRVI Position: Q2 2026 in Review

HSBC Holdings reduced its Trevi Therapeutics (TRVI) stake by 38% in Q2 2026, selling an estimated $94.8K and leaving 10,516 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #2702.

HSBC Holdings first reported a position in TRVI in Q2 2024 and has held it in 8 quarters since. The position peaked at $372K in Q3 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

HSBC Holdings held 10,516 shares of Trevi Therapeutics worth $199K as of Q2 2026.
HSBC Holdings sold 6,518 Trevi Therapeutics shares in Q2 2026, an estimated $94.8K.
Trevi Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2702 holding.
HSBC Holdings first reported a position in Trevi Therapeutics in Q2 2024 and has held it in 8 quarters since.
HSBC Holdings's Trevi Therapeutics position peaked at $372K in Q3 2025.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.